secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001140361-22-027135
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics CSO Kevin D'Amour resigns; effective date TBD
-------------------------------------------------------------------------

- Dr. Kevin D'Amour, Chief Scientific Officer, submitted resignation notice on July 21, 2022.
- Effective date of resignation not yet determined by the Company and Dr. D'Amour.
- No successor or interim CSO announced in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122027135/0001140361-22-027135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122027135/brhc10040035_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-027135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer